Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Merck & Co., Inc. (MRK) Price & Performance

Cassava Sciences IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Merck & Co., Inc. — how do they compare? Cassava Sciences Inc trades at $0.93 (market cap $47.75M), while Merck & Co., Inc. trades at $133.25 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 6738.6× Cassava Sciences Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAMRK
Market Cap
$47.75M$321.77B
Sector
HealthHealth
52-Week High
$4.64$131.84
52-Week Low
$0.87$77.60
Enterprise Value
-$34.93M$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK